Clinical Trials in Ohio

Showing 10261-10280 of 20,938 trials

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

NCT02923466

This is a three-part open label phase 1 study designed to determine the safety profile, MTD, PK and tumor and biomarker response after IT or IV administration of a single dose of VSV-IFNβ-NIS, or combined IT followed by IV VSV-IFNβ-NIS, with or without IV avelumab every two weeks, in patients with refractory advanced/metastatic solid tumors.

Malignant Solid Tumour

Vyriad, Inc.76 participantsStarted Apr 2017

Miami, Florida, United States • Minneapolis, Minnesota, United States • Columbus, Ohio, United States +3 more locations

TERMINATEDPhase 1/232 miles

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

NCT03225846

PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).

Huntington's Disease

Wave Life Sciences Ltd.88 participantsStarted Jul 2017

La Jolla, California, United States • Sacramento, California, United States • Boston, Massachusetts, United States +23 more locations

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Find Trials by Condition in Ohio

CBPR Strategies to Increase Colorectal Cancer Screening in Ohio Appalachia

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Convalescent Plasma to Stem Coronavirus (CSSC-001)

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

A Study of RG-012 in Subjects With Alport Syndrome

Short-term Clinical Deterioration After Acute Pulmonary Embolism

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.